{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T14:57:25Z","timestamp":1793372245183,"version":"4.5.0"},"reference-count":67,"publisher":"eLife Sciences Publications, Ltd","license":[{"start":{"date-parts":[[2023,1,17]],"date-time":"2023-01-17T00:00:00Z","timestamp":1673913600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2023,1,17]],"date-time":"2023-01-17T00:00:00Z","timestamp":1673913600000},"content-version":"am","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2023,1,17]],"date-time":"2023-01-17T00:00:00Z","timestamp":1673913600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003092","name":"Diabetes Fonds","doi-asserted-by":"publisher","award":["2015.81.1808"],"award-info":[{"award-number":["2015.81.1808"]}],"id":[{"id":"10.13039\/501100003092","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003246","name":"Netherlands Organisation for Scientific Research","doi-asserted-by":"publisher","award":["VENI grant 91617027"],"award-info":[{"award-number":["VENI grant 91617027"]}],"id":[{"id":"10.13039\/501100003246","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004543","name":"Chinese Scholarship Council","doi-asserted-by":"crossref","award":["CSC 201606010321"],"award-info":[{"award-number":["CSC 201606010321"]}],"id":[{"id":"10.13039\/501100004543","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100009708","name":"Novo Nordisk Foundation","doi-asserted-by":"publisher","award":["NNF18OC0032394"],"award-info":[{"award-number":["NNF18OC0032394"]}],"id":[{"id":"10.13039\/501100009708","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002996","name":"Hartstichting","doi-asserted-by":"publisher","award":["The Netherlands Cardiovascular Research Initiative CVON-GENIUS-2"],"award-info":[{"award-number":["The Netherlands Cardiovascular Research Initiative CVON-GENIUS-2"]}],"id":[{"id":"10.13039\/501100002996","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elifesciences.org"],"crossmark-restriction":false},"short-container-title":[],"accepted":{"date-parts":[[2023,1,16]]},"abstract":"<jats:p>Analogues of the hepatokine fibroblast growth factor 21 (FGF21) are in clinical development for type 2 diabetes and nonalcoholic steatohepatitis (NASH) treatment. Although their glucose-lowering and insulin-sensitizing effects have been largely unraveled, the mechanisms by which they alleviate liver injury have only been scarcely addressed. Here, we aimed to unveil the mechanisms underlying the protective effects of FGF21 on NASH using APOE*3-Leiden.CETP mice, a well-established model for human-like metabolic diseases. Liver-specific FGF21 overexpression was achieved in mice, followed by administration of a high-fat high-cholesterol diet for 23 weeks. FGF21 prevented hepatic lipotoxicity, accompanied by activation of thermogenic tissues and attenuation of adipose tissue inflammation, improvement of hyperglycemia and hypertriglyceridemia, and upregulation of hepatic programs involved in fatty acid oxidation and cholesterol removal. Furthermore, FGF21 inhibited hepatic inflammation, as evidenced by reduced Kupffer cell (KC) activation, diminished monocyte infiltration, and lowered accumulation of monocyte-derived macrophages. Moreover, FGF21 decreased lipid- and scar-associated macrophages, which correlated with less hepatic fibrosis as demonstrated by reduced collagen accumulation. Collectively, hepatic FGF21 overexpression limits hepatic lipotoxicity, inflammation, and fibrogenesis. Mechanistically, FGF21 blocks hepatic lipid influx and accumulation through combined endocrine and autocrine signaling, respectively, which prevents KC activation and lowers the presence of lipid- and scar-associated macrophages to inhibit fibrogenesis.<\/jats:p>","DOI":"10.7554\/elife.83075","type":"journal-article","created":{"date-parts":[[2023,1,17]],"date-time":"2023-01-17T08:01:19Z","timestamp":1673942479000},"update-policy":"https:\/\/doi.org\/10.7554\/elife.83075","source":"Crossref","is-referenced-by-count":66,"title":["FGF21 protects against hepatic lipotoxicity and macrophage activation to attenuate fibrogenesis in nonalcoholic steatohepatitis"],"prefix":"10.7554","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2852-8953","authenticated-orcid":true,"given":"Cong","family":"Liu","sequence":"first","affiliation":[{"id":[{"id":"https:\/\/ror.org\/05xvt9f17","id-type":"ROR","asserted-by":"publisher"}],"name":"Department of Medicine, Division of Endocrinology, Leiden University Medical Center","place":["Leiden, Netherlands"]},{"id":[{"id":"https:\/\/ror.org\/05xvt9f17","id-type":"ROR","asserted-by":"publisher"}],"name":"Einthoven Laboratory for Experimental Vascular Medicine, Leiden University Medical Center","place":["Leiden, Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Milena","family":"Sch\u00f6nke","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/05xvt9f17","id-type":"ROR","asserted-by":"publisher"}],"name":"Department of Medicine, Division of Endocrinology, Leiden University Medical Center","place":["Leiden, Netherlands"]},{"id":[{"id":"https:\/\/ror.org\/05xvt9f17","id-type":"ROR","asserted-by":"publisher"}],"name":"Einthoven Laboratory for Experimental Vascular Medicine, Leiden University Medical Center","place":["Leiden, Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Borah","family":"Spoorenberg","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/05xvt9f17","id-type":"ROR","asserted-by":"publisher"}],"name":"Department of Medicine, Division of Endocrinology, Leiden University Medical Center","place":["Leiden, Netherlands"]},{"id":[{"id":"https:\/\/ror.org\/05xvt9f17","id-type":"ROR","asserted-by":"publisher"}],"name":"Einthoven Laboratory for Experimental Vascular Medicine, Leiden University Medical Center","place":["Leiden, Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joost M","family":"Lambooij","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/05xvt9f17","id-type":"ROR","asserted-by":"publisher"}],"name":"Department of Parasitology, Leiden University Medical Center","place":["Leiden, Netherlands"]},{"id":[{"id":"https:\/\/ror.org\/05xvt9f17","id-type":"ROR","asserted-by":"publisher"}],"name":"Department of Cell and Chemical Biology, Leiden University Medical Center","place":["Leiden, Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hendrik JP","family":"van der Zande","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/05xvt9f17","id-type":"ROR","asserted-by":"publisher"}],"name":"Department of Parasitology, Leiden University Medical Center","place":["Leiden, Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3739-4934","authenticated-orcid":true,"given":"Enchen","family":"Zhou","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/05xvt9f17","id-type":"ROR","asserted-by":"publisher"}],"name":"Department of Medicine, Division of Endocrinology, Leiden University Medical Center","place":["Leiden, Netherlands"]},{"id":[{"id":"https:\/\/ror.org\/05xvt9f17","id-type":"ROR","asserted-by":"publisher"}],"name":"Einthoven Laboratory for Experimental Vascular Medicine, Leiden University Medical Center","place":["Leiden, Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maarten E","family":"Tushuizen","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/05xvt9f17","id-type":"ROR","asserted-by":"publisher"}],"name":"Department of Gastroenterology and Hepatology, Leiden University Medical Center","place":["Leiden, Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8323-0658","authenticated-orcid":true,"given":"Anne-Christine","family":"Andreasson","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/04wwrrg31","id-type":"ROR","asserted-by":"publisher"}],"name":"Bioscience Metabolism, Research and Early Development, Cardiovascular, Renal and Metabolism (CVRM), BioPharmaceuticals R&D, AstraZeneca","place":["Gothenburg, Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Park","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/043cec594","id-type":"ROR","asserted-by":"publisher"}],"name":"Biologics Engineering and Targeted Delivery, Oncology R&D, AstraZeneca","place":["Gaithersburg, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie","family":"Oldham","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/043cec594","id-type":"ROR","asserted-by":"publisher"}],"name":"Bioscience Metabolism, Research and Early Development, Cardiovascular, Renal and Metabolism (CVRM), BioPharmaceuticals R&D, AstraZeneca","place":["Gaithersburg, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Uhrbom","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/04wwrrg31","id-type":"ROR","asserted-by":"publisher"}],"name":"Bioscience Metabolism, Research and Early Development, Cardiovascular, Renal and Metabolism (CVRM), BioPharmaceuticals R&D, AstraZeneca","place":["Gothenburg, Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ingela","family":"Ahlstedt","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/04wwrrg31","id-type":"ROR","asserted-by":"publisher"}],"name":"Bioscience Metabolism, Research and Early Development, Cardiovascular, Renal and Metabolism (CVRM), BioPharmaceuticals R&D, AstraZeneca","place":["Gothenburg, Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuhiro","family":"Ikeda","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/043cec594","id-type":"ROR","asserted-by":"publisher"}],"name":"Biologics Engineering and Targeted Delivery, Oncology R&D, AstraZeneca","place":["Gaithersburg, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3231-2733","authenticated-orcid":true,"given":"Kristina","family":"Wallenius","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/04wwrrg31","id-type":"ROR","asserted-by":"publisher"}],"name":"Bioscience Metabolism, Research and Early Development, Cardiovascular, Renal and Metabolism (CVRM), BioPharmaceuticals R&D, AstraZeneca","place":["Gothenburg, Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao-Rong","family":"Peng","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/04wwrrg31","id-type":"ROR","asserted-by":"publisher"}],"name":"Bioscience Metabolism, Research and Early Development, Cardiovascular, Renal and Metabolism (CVRM), BioPharmaceuticals R&D, AstraZeneca","place":["Gothenburg, Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruno","family":"Guigas","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/05xvt9f17","id-type":"ROR","asserted-by":"publisher"}],"name":"Department of Parasitology, Leiden University Medical Center","place":["Leiden, Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mari\u00ebtte R","family":"Boon","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/05xvt9f17","id-type":"ROR","asserted-by":"publisher"}],"name":"Department of Medicine, Division of Endocrinology, Leiden University Medical Center","place":["Leiden, Netherlands"]},{"id":[{"id":"https:\/\/ror.org\/05xvt9f17","id-type":"ROR","asserted-by":"publisher"}],"name":"Einthoven Laboratory for Experimental Vascular Medicine, Leiden University Medical Center","place":["Leiden, Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanan","family":"Wang","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/017zhmm22","id-type":"ROR","asserted-by":"publisher"}],"name":"Med-X institute, Center for Immunological and Metabolic Diseases, and Department of Endocrinology, First Affiliated Hospital of Xi'an Jiaotong University, Xi'an Jiaotong University","place":["Xi'an, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8455-4988","authenticated-orcid":true,"given":"Patrick CN","family":"Rensen","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/05xvt9f17","id-type":"ROR","asserted-by":"publisher"}],"name":"Department of Medicine, Division of Endocrinology, Leiden University Medical Center","place":["Leiden, Netherlands"]},{"id":[{"id":"https:\/\/ror.org\/05xvt9f17","id-type":"ROR","asserted-by":"publisher"}],"name":"Einthoven Laboratory for Experimental Vascular Medicine, Leiden University Medical Center","place":["Leiden, Netherlands"]},{"id":[{"id":"https:\/\/ror.org\/017zhmm22","id-type":"ROR","asserted-by":"publisher"}],"name":"Med-X institute, Center for Immunological and Metabolic Diseases, and Department of Endocrinology, First Affiliated Hospital of Xi'an Jiaotong University, Xi'an Jiaotong University","place":["Xi'an, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"4374","published-online":{"date-parts":[[2023,1,17]]},"reference":[{"key":"bib1","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1080\/13543784.2022.2032640","article-title":"Nonalcoholic steatohepatitis (NASH) cirrhosis: a snapshot of therapeutic agents in clinical development and the optimal design for clinical trials","volume":"31","author":"Aggarwal","year":"2022","journal-title":"Expert Opinion on Investigational Drugs"},{"key":"bib2","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1146\/annurev-pathol-020117-043617","article-title":"Recent insights into the pathogenesis of nonalcoholic fatty liver disease","volume":"13","author":"Arab","year":"2018","journal-title":"Annual Review of Pathology"},{"key":"bib3","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1016\/j.jhep.2015.08.038","article-title":"Glucagon-Like peptide 1 decreases lipotoxicity in non-alcoholic steatohepatitis","volume":"64","author":"Armstrong","year":"2016","journal-title":"Journal of Hepatology"},{"key":"bib4","doi-asserted-by":"publisher","first-page":"3379","DOI":"10.1111\/bph.14383","article-title":"A long-acting FGF21 alleviates hepatic steatosis and inflammation in a mouse model of non-alcoholic steatohepatitis partly through an FGF21-adiponectin-IL17A pathway","volume":"175","author":"Bao","year":"2018","journal-title":"British Journal of Pharmacology"},{"key":"bib5","doi-asserted-by":"publisher","first-page":"3327","DOI":"10.1210\/jc.2018-02414","article-title":"Plasma fibroblast growth factor 21 is associated with severity of nonalcoholic steatohepatitis in patients with obesity and type 2 diabetes","volume":"104","author":"Barb","year":"2019","journal-title":"The Journal of Clinical Endocrinology and Metabolism"},{"key":"bib6","doi-asserted-by":"publisher","first-page":"1751","DOI":"10.1002\/hep.25889","article-title":"Histopathological algorithm and scoring system for evaluation of liver lesions in morbidly obese patients","volume":"56","author":"Bedossa","year":"2012","journal-title":"Hepatology"},{"key":"bib7","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms7356","article-title":"Brown fat activation reduces hypercholesterolaemia and protects from atherosclerosis development","volume":"6","author":"Berb\u00e9e","year":"2015","journal-title":"Nature Communications"},{"key":"bib8","doi-asserted-by":"publisher","first-page":"2101","DOI":"10.1016\/j.immuni.2021.08.006","article-title":"A subset of Kupffer cells regulates metabolism through the expression of CD36","volume":"54","author":"Bl\u00e9riot","year":"2021","journal-title":"Immunity"},{"key":"bib9","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1139\/o59-099","article-title":"A rapid method of total lipid extraction and purification","volume":"37","author":"Bligh","year":"1959","journal-title":"Canadian Journal of Biochemistry and Physiology"},{"key":"bib10","doi-asserted-by":"publisher","first-page":"1132","DOI":"10.1002\/hep.28985","article-title":"Metabolic and histological implications of intrahepatic triglyceride content in nonalcoholic fatty liver disease","volume":"65","author":"Bril","year":"2017","journal-title":"Hepatology"},{"key":"bib11","doi-asserted-by":"publisher","first-page":"1026","DOI":"10.1002\/hep.30506","article-title":"The role of innate immune cells in nonalcoholic steatohepatitis","volume":"70","author":"Cai","year":"2019","journal-title":"Hepatology"},{"key":"bib12","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1101\/pdb.prot073411","article-title":"Manual hematoxylin and eosin staining of mouse tissue sections","volume":"2014","author":"Cardiff","year":"2014","journal-title":"Cold Spring Harbor Protocols"},{"key":"bib13","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1053\/j.gastro.2012.02.003","article-title":"Role of obesity and lipotoxicity in the development of nonalcoholic steatohepatitis: pathophysiology and clinical implications","volume":"142","author":"Cusi","year":"2012","journal-title":"Gastroenterology"},{"key":"bib14","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2020.108626","article-title":"Dynamic shifts in the composition of resident and recruited macrophages influence tissue remodeling in NASH","volume":"34","author":"Daemen","year":"2021","journal-title":"Cell Reports"},{"key":"bib15","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1093\/ajcn\/84.1.312","article-title":"Dietary sphingolipids lower plasma cholesterol and triacylglycerol and prevent liver steatosis in APOE*3Leiden mice","volume":"84","author":"Duivenvoorden","year":"2006","journal-title":"The American Journal of Clinical Nutrition"},{"key":"bib16","doi-asserted-by":"publisher","first-page":"1073","DOI":"10.1053\/j.gastro.2014.07.044","article-title":"Fibroblast growth factor 21 limits lipotoxicity by promoting hepatic fatty acid activation in mice on methionine and choline-deficient diets","volume":"147","author":"Fisher","year":"2014","journal-title":"Gastroenterology"},{"key":"bib17","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1146\/annurev-physiol-021115-105339","article-title":"Understanding the physiology of FGF21","volume":"78","author":"Fisher","year":"2016","journal-title":"Annual Review of Physiology"},{"key":"bib18","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1038\/s42255-021-00354-2","article-title":"Metabolic messengers: FGF21","volume":"3","author":"Flippo","year":"2021","journal-title":"Nature Metabolism"},{"key":"bib19","doi-asserted-by":"publisher","first-page":"212","DOI":"10.3164\/jcbn.09-83","article-title":"A mouse model of metabolic syndrome: insulin resistance, fatty liver and non-alcoholic fatty pancreas disease (NAFPD) in C57BL\/6 mice fed a high fat diet","volume":"46","author":"Fraulob","year":"2010","journal-title":"Journal of Clinical Biochemistry and Nutrition"},{"key":"bib20","doi-asserted-by":"publisher","first-page":"908","DOI":"10.1038\/s41591-018-0104-9","article-title":"Mechanisms of NAFLD development and therapeutic strategies","volume":"24","author":"Friedman","year":"2018","journal-title":"Nature Medicine"},{"key":"bib21","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1038\/s41574-020-0386-0","article-title":"The therapeutic potential of FGF21 in metabolic diseases: from bench to clinic","volume":"16","author":"Geng","year":"2020","journal-title":"Nature Reviews. Endocrinology"},{"key":"bib22","doi-asserted-by":"publisher","DOI":"10.1186\/s12944-016-0381-6","article-title":"Fibroblast growth factor 21 potentially inhibits microrna-33 expression to affect macrophage actions","volume":"15","author":"Guo","year":"2016","journal-title":"Lipids in Health and Disease"},{"key":"bib23","doi-asserted-by":"publisher","first-page":"1262","DOI":"10.1038\/s41591-021-01425-3","article-title":"Efruxifermin in non-alcoholic steatohepatitis: a randomized, double-blind, placebo-controlled, phase 2A trial","volume":"27","author":"Harrison","year":"2021","journal-title":"Nature Medicine"},{"key":"bib24","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2021.615978","article-title":"Liver fibrosis in non-alcoholic fatty liver disease: from liver biopsy to non-invasive biomarkers in diagnosis and treatment","volume":"8","author":"Heyens","year":"2021","journal-title":"Frontiers in Medicine"},{"key":"bib25","doi-asserted-by":"publisher","first-page":"2182","DOI":"10.1002\/hep.30113","article-title":"The genetic architecture of diet-induced hepatic fibrosis in mice","volume":"68","author":"Hui","year":"2018","journal-title":"Hepatology"},{"key":"bib26","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1530\/EC-20-0152","article-title":"Fgf21 regulates hepatic metabolic pathways to improve steatosis and inflammation","volume":"9","author":"Keinicke","year":"2020","journal-title":"Endocrine Connections"},{"key":"bib27","doi-asserted-by":"publisher","first-page":"2637","DOI":"10.1007\/s00125-015-3727-0","article-title":"Central GLP-1 receptor signalling accelerates plasma clearance of triacylglycerol and glucose by activating brown adipose tissue in mice","volume":"58","author":"Kooijman","year":"2015","journal-title":"Diabetologia"},{"key":"bib28","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1038\/nri.2017.11","article-title":"Liver macrophages in tissue homeostasis and disease","volume":"17","author":"Krenkel","year":"2017","journal-title":"Nature Reviews. Immunology"},{"key":"bib29","doi-asserted-by":"publisher","first-page":"1270","DOI":"10.1002\/hep.29544","article-title":"Therapeutic inhibition of inflammatory monocyte recruitment reduces steatohepatitis and liver fibrosis","volume":"67","author":"Krenkel","year":"2018","journal-title":"Hepatology"},{"key":"bib30","doi-asserted-by":"publisher","first-page":"G107","DOI":"10.1152\/ajpgi.00391.2009","article-title":"Kupffer cell activation is a causal factor for hepatic insulin resistance","volume":"298","author":"Lanthier","year":"2010","journal-title":"American Journal of Physiology. Gastrointestinal and Liver Physiology"},{"key":"bib31","doi-asserted-by":"publisher","first-page":"934","DOI":"10.1016\/j.jhep.2010.05.018","article-title":"Fibroblast growth factor 21 levels are increased in nonalcoholic fatty liver disease patients and are correlated with hepatic triglyceride","volume":"53","author":"Li","year":"2010","journal-title":"Journal of Hepatology"},{"key":"bib32","doi-asserted-by":"publisher","first-page":"1269","DOI":"10.1136\/gutjnl-2017-314050","article-title":"Butyrate reduces appetite and activates brown adipose tissue via the gut-brain neural circuit","volume":"67","author":"Li","year":"2018","journal-title":"Gut"},{"key":"bib33","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0115922","article-title":"Establishment of a general NAFLD scoring system for rodent models and comparison to human liver pathology","volume":"9","author":"Liang","year":"2014","journal-title":"PLOS ONE"},{"key":"bib34","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1016\/j.cmet.2013.04.005","article-title":"Adiponectin mediates the metabolic effects of FGF21 on glucose homeostasis and insulin sensitivity in mice","volume":"17","author":"Lin","year":"2013","journal-title":"Cell Metabolism"},{"key":"bib35","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1093\/cvr\/cvab076","article-title":"Pharmacological treatment with FGF21 strongly improves plasma cholesterol metabolism to reduce atherosclerosis","volume":"118","author":"Liu","year":"2022","journal-title":"Cardiovascular Research"},{"key":"bib36","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhepr.2021.100392","article-title":"Pegbelfermin selectively reduces secondary bile acid concentrations in patients with non-alcoholic steatohepatitis","volume":"4","author":"Luo","year":"2022","journal-title":"JHEP Reports"},{"key":"bib37","doi-asserted-by":"publisher","first-page":"1769","DOI":"10.1053\/j.gastro.2016.02.066","article-title":"Pathogenesis of nonalcoholic steatohepatitis","volume":"150","author":"Machado","year":"2016","journal-title":"Gastroenterology"},{"key":"bib38","doi-asserted-by":"publisher","first-page":"4057","DOI":"10.2337\/db14-0595","article-title":"Circulating FGF21 is liver derived and enhances glucose uptake during refeeding and overfeeding","volume":"63","author":"Markan","year":"2014","journal-title":"Diabetes"},{"key":"bib39","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.150249","article-title":"The mir-182-5p\/FGF21\/acetylcholine axis mediates the crosstalk between adipocytes and macrophages to promote beige fat thermogenesis","volume":"6","author":"Meng","year":"2021","journal-title":"JCI Insight"},{"key":"bib40","doi-asserted-by":"publisher","first-page":"1180","DOI":"10.1016\/j.jhep.2014.12.011","article-title":"Mirtoselect, an anthocyanin-rich bilberry extract, attenuates non-alcoholic steatohepatitis and associated fibrosis in ApoE (\u2217) 3leiden mice","volume":"62","author":"Morrison","year":"2015","journal-title":"Journal of Hepatology"},{"key":"bib41","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1038\/ijo.2015.226","article-title":"Surgical removal of inflamed epididymal white adipose tissue attenuates the development of non-alcoholic steatohepatitis in obesity","volume":"40","author":"Mulder","year":"2016","journal-title":"International Journal of Obesity"},{"key":"bib42","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.plipres.2008.08.001","article-title":"Recent insights into hepatic lipid metabolism in non-alcoholic fatty liver disease (NAFLD)","volume":"48","author":"Musso","year":"2009","journal-title":"Progress in Lipid Research"},{"key":"bib43","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-99-118334","article-title":"Adeno-associated mediated gene transfer for hemophilia B:8 year follow up and impact of removing \u201c empty viral particles\u201d on safety and efficacy of gene transfer","volume":"132","author":"Nathwani","year":"2018","journal-title":"Blood"},{"key":"bib44","doi-asserted-by":"publisher","first-page":"774","DOI":"10.1002\/hep.23719","article-title":"Hepatic lipotoxicity and the pathogenesis of nonalcoholic steatohepatitis: the central role of nontriglyceride fatty acid metabolites","volume":"52","author":"Neuschwander-Tetri","year":"2010","journal-title":"Hepatology"},{"key":"bib45","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1016\/s0167-4781(00)00067-1","article-title":"Identification of a novel FGF, FGF-21, preferentially expressed in the liver","volume":"1492","author":"Nishimura","year":"2000","journal-title":"Biochimica et Biophysica Acta"},{"key":"bib46","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1038\/s41586-019-1631-3","article-title":"Resolving the fibrotic niche of human liver cirrhosis at single-cell level","volume":"575","author":"Ramachandran","year":"2019","journal-title":"Nature"},{"key":"bib47","doi-asserted-by":"publisher","first-page":"1825","DOI":"10.1038\/s41591-021-01495-3","article-title":"Aramchol in patients with nonalcoholic steatohepatitis: a randomized, double-blind, placebo-controlled phase 2B trial","volume":"27","author":"Ratziu","year":"2021","journal-title":"Nature Medicine"},{"key":"bib48","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1016\/j.immuni.2020.08.004","article-title":"Osteopontin expression identifies a subset of recruited macrophages distinct from Kupffer cells in the fatty liver","volume":"53","author":"Remmerie","year":"2020","journal-title":"Immunity"},{"key":"bib49","doi-asserted-by":"publisher","first-page":"2705","DOI":"10.1016\/S0140-6736(18)31785-9","article-title":"Pegbelfermin (BMS-986036), a pegylated fibroblast growth factor 21 analogue, in patients with non-alcoholic steatohepatitis: a randomised, double-blind, placebo-controlled, phase 2A trial","volume":"392","author":"Sanyal","year":"2019","journal-title":"Lancet"},{"key":"bib50","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1016\/j.cmet.2016.01.006","article-title":"Fgf21 lowers plasma triglycerides by accelerating lipoprotein catabolism in white and brown adipose tissues","volume":"23","author":"Schlein","year":"2016","journal-title":"Cell Metabolism"},{"key":"bib51","doi-asserted-by":"publisher","first-page":"1913","DOI":"10.1053\/j.gastro.2019.11.311","article-title":"Mechanisms of fibrosis development in nonalcoholic steatohepatitis","volume":"158","author":"Schwabe","year":"2020","journal-title":"Gastroenterology"},{"key":"bib52","doi-asserted-by":"publisher","first-page":"1057","DOI":"10.1016\/j.immuni.2020.04.001","article-title":"Niche-specific reprogramming of epigenetic landscapes drives myeloid cell diversity in nonalcoholic steatohepatitis","volume":"52","author":"Seidman","year":"2020","journal-title":"Immunity"},{"key":"bib53","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1016\/S2213-8587(18)30154-2","article-title":"Non-Alcoholic fatty liver disease: causes, diagnosis, cardiometabolic consequences, and treatment strategies","volume":"7","author":"Stefan","year":"2019","journal-title":"The Lancet. Diabetes & Endocrinology"},{"key":"bib54","doi-asserted-by":"publisher","first-page":"1300","DOI":"10.1016\/j.jhep.2017.02.026","article-title":"Targeting hepatic macrophages to treat liver diseases","volume":"66","author":"Tacke","year":"2017","journal-title":"Journal of Hepatology"},{"key":"bib55","doi-asserted-by":"publisher","first-page":"1611","DOI":"10.1053\/j.gastro.2020.01.043","article-title":"Association between fibrosis stage and outcomes of patients with nonalcoholic fatty liver disease: a systematic review and meta-analysis","volume":"158","author":"Taylor","year":"2020","journal-title":"Gastroenterology"},{"key":"bib56","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1016\/j.immuni.2020.06.003","article-title":"Impaired Kupffer cell self-renewal alters the liver response to lipid overload during non-alcoholic steatohepatitis","volume":"53","author":"Tran","year":"2020","journal-title":"Immunity"},{"key":"bib57","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1016\/s1050-1738(00)00043-8","article-title":"Fxr, a bile acid receptor and biological sensor","volume":"10","author":"Tu","year":"2000","journal-title":"Trends in Cardiovascular Medicine"},{"key":"bib58","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1111\/dom.12252","article-title":"APOE*3Leiden.CETP transgenic mice as model for pharmaceutical treatment of the metabolic syndrome","volume":"16","author":"van den Hoek","year":"2014","journal-title":"Diabetes, Obesity & Metabolism"},{"key":"bib59","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.1111\/j.1476-5381.2008.00109.x","article-title":"The dual PPARalpha\/gamma agonist tesaglitazar blocks progression of pre-existing atherosclerosis in APOE*3leiden.CETP transgenic mice","volume":"156","author":"van der Hoorn","year":"2009","journal-title":"British Journal of Pharmacology"},{"key":"bib60","doi-asserted-by":"publisher","DOI":"10.1096\/fj.202001973R","article-title":"The helminth glycoprotein omega-1 improves metabolic homeostasis in obese mice through type 2 immunity-independent inhibition of food intake","volume":"35","author":"van der Zande","year":"2021","journal-title":"FASEB Journal"},{"key":"bib61","doi-asserted-by":"publisher","first-page":"2552","DOI":"10.1161\/01.ATV.0000243925.65265.3c","article-title":"Cholesteryl ester transfer protein decreases high-density lipoprotein and severely aggravates atherosclerosis in APOE*3-leiden mice","volume":"26","author":"Westerterp","year":"2006","journal-title":"Arteriosclerosis, Thrombosis, and Vascular Biology"},{"key":"bib62","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1038\/s41580-018-0044-8","article-title":"Metabolites as regulators of insulin sensitivity and metabolism","volume":"19","author":"Yang","year":"2018","journal-title":"Nature Reviews. Molecular Cell Biology"},{"key":"bib63","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1172\/JCI121842","article-title":"Sting-Mediated inflammation in Kupffer cells contributes to progression of nonalcoholic steatohepatitis","volume":"129","author":"Yu","year":"2019","journal-title":"The Journal of Clinical Investigation"},{"key":"bib64","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1016\/j.tips.2019.12.005","article-title":"Targeting FGF21 for the treatment of nonalcoholic steatohepatitis","volume":"41","author":"Zarei","year":"2020","journal-title":"Trends in Pharmacological Sciences"},{"key":"bib65","doi-asserted-by":"publisher","first-page":"1246","DOI":"10.2337\/db07-1476","article-title":"Serum FGF21 levels are increased in obesity and are independently associated with the metabolic syndrome in humans","volume":"57","author":"Zhang","year":"2008","journal-title":"Diabetes"},{"key":"bib66","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1016\/j.ebiom.2016.12.016","article-title":"Chronic over-expression of fibroblast growth factor 21 increases bile acid biosynthesis by opposing FGF15\/19 action","volume":"15","author":"Zhang","year":"2017","journal-title":"EBioMedicine"},{"key":"bib67","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1016\/j.cmet.2017.12.004","article-title":"An adipose tissue atlas: an image-guided identification of human-like bat and beige depots in rodents","volume":"27","author":"Zhang","year":"2018","journal-title":"Cell Metabolism"}],"container-title":["eLife"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/cdn.elifesciences.org\/articles\/83075\/elife-83075-v2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/cdn.elifesciences.org\/articles\/83075\/elife-83075-v2.xml","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/elifesciences.org\/articles\/83075","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,11]],"date-time":"2023-10-11T21:09:32Z","timestamp":1697058572000},"score":1,"resource":{"primary":{"URL":"https:\/\/elifesciences.org\/articles\/83075"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,17]]},"references-count":67,"alternative-id":["10.7554\/eLife.83075"],"URL":"https:\/\/doi.org\/10.7554\/elife.83075","archive":["CLOCKSS"],"relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2022.09.20.508654","asserted-by":"subject"}],"has-review":[{"id-type":"doi","id":"10.7554\/eLife.83075.sa2","asserted-by":"object"},{"id-type":"doi","id":"10.7554\/eLife.83075.sa0","asserted-by":"object"},{"id-type":"doi","id":"10.7554\/eLife.83075.sa1","asserted-by":"object"}]},"ISSN":["2050-084X"],"issn-type":[{"value":"2050-084X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,1,17]]},"assertion":[{"value":"single anonymised","name":"peer_review_transparency","label":"Peer review transparency","group":{"name":"peer_review_taxonomy"}},{"value":"other reviewer(s), editor","name":"peer_review_interaction","label":"Peer review interaction","group":{"name":"peer_review_taxonomy"}},{"value":"review summaries, review reports, author\/editor communication, reviewer identities reviewer opt in, editor identities","name":"peer_review_published","label":"Peer review published","group":{"name":"peer_review_taxonomy"}},{"value":"open (sign in with ORCID iD required)","name":"post_publication_commenting","label":"Post publication commenting","group":{"name":"post_publication_commenting"}}],"article-number":"e83075"}}